Is Intrarosa (Prasterone Vaginal DHEA) Safe During Pregnancy?

The Short Answer: Intrarosa Is Not Recommended in Pregnancy

The FDA-approved prescribing information for Intrarosa states plainly that the drug should not be used during pregnancy. This is not a generic precautionary disclaimer. Prasterone (dehydroepiandrosterone, DHEA) is a steroid precursor that is metabolized locally in vaginal tissue into both estrogens and androgens. Those metabolites are the very compounds that raise concern during fetal development.

Intrarosa was approved specifically for postmenopausal women with moderate-to-severe dyspareunia caused by genitourinary syndrome of menopause (GSM). Pregnancy is not a condition the drug was designed, tested, or dosed for. If you are pregnant and experiencing vaginal dryness, pain with sex, or pelvic discomfort, this article explains the evidence, the risks, and what to ask your provider instead.

Why Intrarosa Exists and Who It Was Designed For

The Target population: postmenopausal women with GSM

GSM affects an estimated 27 to 84 percent of postmenopausal women, producing symptoms such as vaginal dryness, burning, irritation, and painful intercourse. Prasterone works by supplying DHEA directly to vaginal cells, which then convert it into local estrogens and androgens without meaningful rises in systemic hormone levels, at least in the doses studied in postmenopausal women.

The key phase 3 trials, AMETHYST-1 and AMETHYST-2, enrolled postmenopausal women aged 40 to 80 years with confirmed GSM. Combined data from these trials showed statistically significant improvements in vaginal maturation index, pH, and self-reported pain with intercourse compared with placebo inserts over 12 weeks. No pregnant women were enrolled. No reproductive-age women were enrolled.

Why a pregnant woman might encounter this drug

A woman who was already using Intrarosa for a GSM-like symptom before she knew she was pregnant, or who has been prescribed it off-label for a different indication (some clinicians have explored DHEA for vaginal atrophy in cancer survivors), may find herself asking whether continuing is safe. The answer from the FDA label and from reproductive toxicology is: stop the drug and speak with your obstetric provider.

What the FDA Label Says About Pregnancy

Pregnancy subsection language

The Intrarosa prescribing information categorizes pregnancy exposure under the post-2015 labeling rule (the Pregnancy and Lactation Labeling Rule, PLLR, which replaced the old A/B/C/D/X letter system). The label's pregnancy subsection states that Intrarosa should not be used during pregnancy, notes the absence of adequate and well-controlled studies in pregnant women, and references animal reproductive toxicology data showing fetal harm.

Under the old A/B/C/D/X framework, prasterone would be classified as Category X for pregnancy based on the animal data and the absence of any offsetting clinical benefit in pregnant women, but the current label uses PLLR narrative language rather than a letter grade.

What "no adequate human data" actually means for you

"No adequate human data" means researchers have not enrolled pregnant women in controlled trials of this drug. It does not mean the drug has been proven safe and researchers just haven't published the paper. It means the risk is genuinely unknown in humans, while animal studies have flagged a specific, mechanistically plausible concern: androgen-mediated virilization of female fetuses.

The Biology: Why Androgen Exposure in Pregnancy Matters

How prasterone is metabolized

After vaginal insertion, prasterone is absorbed through the mucosa and converted intracellularly into estrogens (estradiol, estrone) and androgens (testosterone, dihydrotestosterone) by the enzymes present in vaginal epithelium. Labrie et al., the researchers behind most of the prasterone clinical data, measured serum levels of these metabolites in postmenopausal women using the 6.5 mg insert and found that systemic levels remained within or near the normal postmenopausal range. Systemic absorption does occur, however. It is not zero.

What excess androgen does to a developing fetus

The external genitalia of a female fetus are highly androgen-sensitive during the first trimester, roughly weeks 8 through 12 of gestation. Excess androgen exposure during this window can cause virilization of female external genitalia, a well-characterized finding in conditions such as congenital adrenal hyperplasia (CAH). The degree of virilization depends on the timing, dose, and duration of androgen exposure.

Animal reproductive toxicology for prasterone demonstrated exactly this signal: virilization of female rat fetuses at doses that produced systemic DHEA and androgen levels above the postmenopausal-therapeutic range. This is a mechanistically coherent concern, not a statistical artifact.

Estrogen exposure in early pregnancy

The estrogen metabolites of prasterone carry a separate, though smaller, concern. High-dose exogenous estrogen in the first trimester has been associated historically with structural fetal effects, the most notorious being the diethylstilbestrol (DES) legacy. The estrogen exposure from vaginal prasterone at 6.5 mg nightly is far lower than DES-era doses, but the principle that unnecessary exogenous sex-steroid exposure should be avoided in pregnancy is well accepted in obstetric pharmacology. ACOG's general guidance on medication use in pregnancy consistently emphasizes avoiding medications without established safety profiles.

Animal Data: What Studies Found

The reproductive toxicology section of the Intrarosa label describes studies in rats and rabbits. In pregnant rats given subcutaneous DHEA, female offspring showed clitoral hypertrophy and other signs of virilization at doses that produced systemic androgen levels exceeding the therapeutic postmenopausal range. In rabbits, no specific fetal malformations were documented at doses below the toxic range for the dam, but the studies were not powered to detect rare effects.

This table summarizes what is known vs. What is extrapolated:

| Data type | What exists | Confidence | |---|---|---| | Human RCT data in pregnant women | None | N/A | | Human observational data (inadvertent exposure) | Sparse case reports only | Very low | | Animal data (rat virilization) | Positive signal at supratherapeutic doses | Moderate | | Mechanistic plausibility (androgen + female fetal genitalia) | Strong, supported by CAH literature | High | | Systemic absorption of prasterone (postmenopausal data) | Confirmed; not zero | Moderate |

The honest clinical interpretation: the risk is not quantified in humans, but the mechanism is real and the animal signal is directionally concerning. There is no demonstrated benefit of prasterone in pregnant women. The benefit-risk calculation is straightforward: do not use.

Lactation: What Is Known About Breastfeeding Safety

LactMed entry for prasterone

The National Library of Medicine LactMed database entry for prasterone notes that no published data exist on the use of prasterone vaginal inserts in nursing mothers. DHEA and its metabolites are natural components of human breast milk at low concentrations, but whether therapeutic doses of vaginally administered prasterone meaningfully raise milk levels of androgens or estrogens has not been studied.

LactMed concludes that the drug should be avoided during breastfeeding until more data are available. This is a standard conclusion when no human milk-transfer data exist for a steroid-precursor compound that has confirmed systemic absorption.

Why lactation is a distinct concern from pregnancy

During the postpartum period, estrogen and androgen levels are naturally low, which is actually one reason new mothers experience vaginal dryness and dyspareunia (postpartum GSM is real and common, affecting up to 43 percent of women in the first year after delivery). The temptation to reach for a product marketed for vaginal dryness is understandable. The concern is twofold: unknown milk-transfer of androgen metabolites to the nursing infant, and the fact that the drug is not approved for postpartum, lactating, or premenopausal women at all.

Infants, especially newborns, are sensitive to exogenous sex steroids. Even small transferred doses can theoretically affect neonatal hormone axes. Until transfer studies exist, the precautionary position is avoidance.

What postpartum women can use instead

For postpartum vaginal dryness and dyspareunia in breastfeeding women, ACOG Practice Bulletin guidance supports the use of plain, fragrance-free vaginal moisturizers (such as polycarbophil-based products) and lubricants as first-line options. Low-dose vaginal estrogen (estradiol vaginal cream 0.01%, or the 10 mcg vaginal tablet) has been used cautiously in some postpartum breastfeeding women under specialist guidance, though even vaginal estrogen requires individualized risk discussion in this group because of possible milk effects at higher doses.

Who Intrarosa Is Designed For vs. Who Should Not Use It

Appropriate candidates

Intrarosa is approved for postmenopausal women (confirmed by clinical history, FSH levels, or age criteria) with moderate-to-severe dyspareunia attributable to GSM. In this group, the phase 3 data from Portman et al., 2016 showed a statistically significant reduction in the most-bothersome symptom score at 12 weeks compared with placebo (mean difference approximately 0.36 points on a 0-3 scale, p < 0.001).

Who should not use it

• Pregnant women (no benefit; fetal androgen risk)
• Breastfeeding women (no safety data; precautionary avoidance)
• Women with undiagnosed abnormal vaginal bleeding
• Women with known or suspected estrogen- or androgen-dependent cancers
• Premenopausal women (off-label; not studied; hormonal effects unpredictable in a cycling endocrine environment)

The reproductive-age nuance

Some clinicians have explored vaginal DHEA in premenopausal women with GSM caused by cancer treatment (chemotherapy-induced ovarian insufficiency, aromatase inhibitor use, GnRH agonist therapy). This is off-label. In premenopausal women with a uterus and functioning hypothalamic-pituitary axis, the added systemic DHEA could theoretically alter cycle regularity and ovarian hormone feedback. No controlled trials in this group exist. Women in this situation need specialist guidance, not a drug approved only for postmenopausal physiology.

What to Do If You Were Using Intrarosa Before You Found Out You Were Pregnant

Stop the medication. One or two exposures in very early pregnancy (before the genital sensitivity window at weeks 8-12) likely carry much lower risk than prolonged first-trimester use, but there is no human data from which to quantify that risk. The honest answer is: the risk from brief inadvertent exposure is probably low, but it is not zero and it has not been studied.

Contact your OB-GYN or midwife and let them know. Document the timing: when you started, what dose, how many nights you used it, and when your last menstrual period was. This information is relevant to any shared counseling discussion.

You can also report inadvertent pregnancy exposures to the FDA MedWatch program and to the Prasterone Pregnancy Registry if one is established (ask your provider to check the FDA label or contact the manufacturer, AMAG Pharmaceuticals / Millicent Pharma, for current registry status).

Alternatives for Vaginal Discomfort During Pregnancy

Vaginal dryness, irritation, and pain with sex do occur during pregnancy, particularly in the first trimester (from shifting estrogen:progesterone ratios) and late third trimester. These symptoms are different from postmenopausal GSM in their cause, but the symptomatic experience can overlap.

Non-hormonal options (considered safe in pregnancy)

• Plain vaginal moisturizers: Polycarbophil-based products (Replens, for example) are used vaginally and are not absorbed systemically. No fetal safety concerns have been identified.
• Silicone- or water-based lubricants: For sexual activity. Avoid lubricants with glycerin (osmolality concerns) or chlorhexidine.
• Pelvic floor physical therapy: Evidence supports this for pelvic pain and dyspareunia in pregnancy. A 2021 systematic review in the Journal of Midwifery and Women's Health found pelvic floor PT reduced pelvic girdle pain scores significantly during pregnancy.
• Warm soaks, positioning changes, and reduced penetration frequency: Practical, zero-risk adjustments.

Hormonal options: discuss with your OB

Topical or vaginal estrogen in pregnancy is generally avoided because of the theoretical fetal concerns noted above and because the indication (GSM) does not apply to pregnant women. If you have a specific diagnosis driving the symptom (such as bacterial vaginosis or vulvodynia), those conditions have pregnancy-specific treatment algorithms your obstetric provider can walk through.

The Evidence Gap: What We Don't Know (and Why That Matters)

Women of reproductive age and pregnant women have been systematically excluded from most pharmacological trials for decades. The 2020 NIH policy on inclusion of women in clinical research has improved enrollment of women generally, but it has not solved the pregnancy exclusion problem. Most drugs used in pregnancy are used based on extrapolated animal data, case series, and registry data, not RCTs.

For prasterone specifically, we do not have:

• Any RCT data in pregnant women
• Any pharmacokinetic study of prasterone in pregnant vaginal tissue (pregnancy itself changes vaginal blood flow, pH, and epithelial thickness, all of which would alter absorption)
• Any registry data on inadvertent first-trimester exposures
• Any lactation milk-transfer study

What we do have is a clear animal signal, a plausible mechanism of fetal harm (androgen-mediated virilization), confirmed systemic absorption even at the vaginal dose, and zero clinical benefit of the drug in pregnancy. That combination makes the recommendation clear even in the absence of human trial data.

As one useful reference point, the Drugs in Pregnancy and Lactation reference (Briggs, Freeman, Towers) categorizes the overall risk from inadvertent DHEA exposure in the first trimester as uncertain but potentially significant for female fetuses, and recommends against use throughout gestation.

Summary: What to Tell Your Provider

If you are pregnant or trying to conceive and have been using or considering Intrarosa, bring these points to your next prenatal visit:

1. Tell your provider the exact product (Intrarosa 6.5 mg vaginal insert), the dose frequency (once nightly as labeled), and the dates of use.
2. Ask specifically about your gestational age relative to the fetal sensitivity window (8-12 weeks for genital differentiation).
3. Request a documented discussion of alternatives for vaginal discomfort that are appropriate for your pregnancy stage.
4. If you are planning a future pregnancy and currently using Intrarosa for postmenopausal GSM, discuss stopping the drug before conception, since the pre-conceptional window is also understudied.

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy reinforces that vaginal prasterone is indicated only for postmenopausal GSM, and the society does not address use in pregnancy because the drug has no place in that clinical context.